Atlantic Healthcare Reports Results from Phase 1 Trial of Tablet for Crohns CAMBRIDGE, UK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Oral Alicaforsen Appears Safe and Well-Tolerated via NEWMEDIAWIRE – Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist...

Atlantic Healthcare completes patient enrollment to its Phase 3 study of alicaforsen to treat IBD Pouchitis Study completion and top-line data expected in Q1 2019 CAMBRIDGE, U.K., May 02, 2018 (GLOBE NEWSWIRE) -- Atlantic Healthcare plc (Atlantic Healthcare), an emerging trans-Atlantic pharmaceutical...

Atlantic Healthcare develops tablet formulations of alicaforsen to treat Crohn's disease and Ulcerative Colitis CAMBRIDGE, U.K., May 30, 2017 (GLOBE NEWSWIRE) -- Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI)...

Atlantic Healthcare announces strengthening of the Board as it prepares for commercialisation of alicaforsen in its first indication CAMBRIDGE, U.K., May 22, 2017 (GLOBE NEWSWIRE) -- Atlantic Healthcare plc (“Atlantic Healthcare”), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI)...